Article Text

Download PDFPDF
Dramatic improvement of bullous pemphigoid with omalizumab in an elderly patient
  1. Francisco J Navarro-Triviño1,
  2. Jose Maria Llamas-Molina1,
  3. Angela Ayen-Rodriguez1,
  4. Barbara Cancela-Díez2,
  5. Ricardo Ruiz-Villaverde1
  1. 1Dermatology, Hospital Universitario San Cecilio, Granada, Andalucía, Spain
  2. 2Pharmacy, Hospital Universitario San Cecilio, Granada, Andalucía, Spain
  1. Correspondence to Dr Ricardo Ruiz-Villaverde, Dermatology, Hospital Universitario San Cecilio, Granada, Spain; ismenios{at}hotmail.com

Abstract

A 70-year-old man with a history of hypertension was evaluated in our dermatology department due to the appearance of a clinical picture compatible with bullous pemphigoid that was confirmed histologically. The lack of response to topical and systemic immunosuppressive treatment resulted in omalizumab being prescribed in a multidisciplinary committee based on the clinical and analytical findings and the patient’s refusal to be treated with rituximab. The evaluation at 3 months showed the absence of blisters on the clinical examination. No associated adverse effects were observed. In the following 3 months the patient was administered medication at home in the absence of an anaphylactic reaction and with prior training by the nursing staff of the Hospital Pharmacy Service. After 6 months the medication was suspended with no relapses for 6 months since the last dose. Omalizumab, an anti-IgE monoclonal drug which has a good safety profile with minimum adverse side effects should be considered when there is a contraindication to the use of intravenous therapies (eg, immunoglobulins, rituximab) or prolonged immunosuppressive treatment (eg, methotrexate, azathioprine).

  • allergy and immunology
  • clinical medicine
  • safety
  • dermatology
  • social medicine
View Full Text

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.